Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study

References

• Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009;53:171–84
   PubMed Web of Science ®Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765–8
   PubMed Web of Science ®Google Scholar
• Soulié M, Beuzeboc P, Cornud F, et al. Cancer de la prostate. Progr Urol 2007;17:1159–230
   PubMedGoogle Scholar
• Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol 2008;10:111–9
   PubMedGoogle Scholar
• Damber J, Aus G. Prostate cancer. Lancet 2008;371:1710–21
   PubMed Web of Science ®Google Scholar
• Baade PD, Coory MD, Aitken JF. International trends in prostate-cancer mortality: the decrease in continuing and spreading. Cancer Causes Control 2004;15:237–41
   PubMedGoogle Scholar
• Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997;79:235–46
   PubMedGoogle Scholar
• Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238–44
   PubMed Web of Science ®Google Scholar
• Loblaw DA, Virgo KS, Nam R, et al. American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596–605
   PubMed Web of Science ®Google Scholar
• Bolla M, de Reijke TM, Van Tienhoven G, et al. EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–27
   PubMed Web of Science ®Google Scholar
• Souhami L, Bae K, Pilepich M, Sandler H. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 2009;27:2137–43
   PubMed Web of Science ®Google Scholar
• Lu-Yao G, Stukel TA, Yao SL. Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 2004;171:2285–90
   PubMed Web of Science ®Google Scholar
• Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison non-prostate cancer cohort. J Natl Cancer Inst 2000;92:613–21
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–7
   PubMed Web of Science ®Google Scholar
• Higano C. Androgen deprivation therapy: monitoring and managing the complications. Hematol Oncol Clin North Am 2006;20:909–23
   PubMed Web of Science ®Google Scholar
• Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with non metastatic prostate cancer. J Urol 2006;176:2443–7
   PubMed Web of Science ®Google Scholar
• Mohile SG, Bylow K, Dale W, et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 2007;109:802–10
   PubMed Web of Science ®Google Scholar
• Karnofsky, DA, Burchenal, JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949:196
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76
   PubMed Web of Science ®Google Scholar
• Fayers P, Aaronson NK, Bjordal K, et al. on behalf of the EORTC Quality of Life Study Group. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: EORTC Quality of Life Group; 2001:86 pp
   Google Scholar
• Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res 1996;5:212–22
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168:9–12
   PubMed Web of Science ®Google Scholar
• Isbarn H, Boccon-Gibod L, Carroll PR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2008;55:62–75
   PubMed Web of Science ®Google Scholar
• Michaelson MD, Cotter SE, Gargollo PC, et al. Management of complications of prostate cancer treatment. CA Cancer J Clin 2008;58:196–213
   PubMed Web of Science ®Google Scholar
• Harle LK, Maggio M, Shahani S, et al. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 2006;4:687–96
   PubMedGoogle Scholar
• Hakimian P, Blute Jr M, Kashanian J, et al. Metabolic and cardiovascular effects of androgen deprivation therapy. BJU Int 2008;102:1509–14
   PubMed Web of Science ®Google Scholar
• Borghede G, Karlsson J, Sullivan M. Quality of life in patients with prostatic cancer: results form a Swedish population study. J Urol 1997;158:1477–86
   PubMedGoogle Scholar
• Pinkawa M, Fischedick K, Gagel B, et al. Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment. BMC Cancer 2009;9:296
   PubMedGoogle Scholar
• Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762–74
   PubMed Web of Science ®Google Scholar
• Morreale MK. The impact of cancer on sexual function. Adv Psychosom Med 2011;31:72–82
   PubMed Web of Science ®Google Scholar
• Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 2011;29:89–96
   PubMed Web of Science ®Google Scholar
• You D, Jeong IG, Kim SW, et al. Impacts of leuprolide acetate on quality of life in patients with prostate cancer: a prospective multicenter study. Scand J Urol Nephrol 2010;44:399–405
   PubMed Web of Science ®Google Scholar
• Herr HW, O’Sullivan M. Quality of life of asymptomatic men with non-metastatic prostate cancer on androgen deprivation therapy. J Urol 2000;163:1743–6
   PubMed Web of Science ®Google Scholar
• Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008;113:1097–106
   PubMed Web of Science ®Google Scholar
• Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750–7
   PubMed Web of Science ®Google Scholar
• Cassileth BR, Soloway MS, Vogelzang NJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res 1992;1:323–9
   PubMedGoogle Scholar
• Albertsen PC, Aaronson NK, Muller MJ, et al. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997;49:207–16
   PubMed Web of Science ®Google Scholar
• Litwin MS, Shpall AI, Dorey F, Nguyen TH. Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 1998;21:327–32
   PubMed Web of Science ®Google Scholar
• Chassany O, Sagnier P, Marquis P, et al. Patient-reported outcomes: the example of health-related quality of life: a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002;36:209–38
   Web of Science ®Google Scholar